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diabetes-related complications resulting in improved quality of life and increased 
survival rates.
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Objectives: In spite of the national screening program, evidence is lacking on the 
health benefits such as decrease in complications and cost of screening of diabetes. 
Little is known about cost-effectiveness of national diabetes screening program. 
The purpose of this study is to evaluate cost-effectiveness of the current national 
screening program of type 2 diabetes in South Korea. MethOds: A Markov model 
for type 2 diabetes that reflected current national screening program was developed. 
This model analyzed the effects of screening for the population aged 40 and older 
with first and second FPG (fasting plasma glucose) tests. Data sources for the model 
parameters included the National Health and Nutrition Examination Survey data 
for cohort characteristics, the National Health Insurance claims data (HIRA-NPS) for 
costs, and published literature for other epidemiology data, treatment effects and 
utility pertaining to diabetes patients. From a payer’s perspective, cost per life-year 
gained (LYG) and cost per quality-adjusted life-year (QALY) gained from screening 
compared with no screening were calculated based on lifetime costs and accumu-
lated LYGs and QALYs. One-way sensitivity analyses were carried out. Results: The 
incremental cost-effectiveness ratio (ICER) was higher than 84 million KRW per LYG 
and higher than 94 million KRW per QALY. The superior strategy in screening inter-
val was identified as every two year. The results of sensitivity analysis showed that 
older age, higher participation rates of second FPG test, and higher rates of glucose 
control could improve cost-effectiveness of diabetes screening. cOnclusiOns: The 
current national diabetes screening program was not cost-effective considering GDP 
per capita or willingness-to-pay per QALY. Policies to improve participation rates 
in second screening test need to be established since higher second screening rate 
leads to positive impacts on ICER and screening interval. Also, effective diabetes 
management program for diagnosed patients after screening is required as glucose 
control is related to ICER improvement.
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Objectives: Endometriosis is a gynecological disease that affects the quality of life 
of women of reproductive age and is costly to treat. The purpose of the review was 
to determine if early detection of endometriosis reduces the costs and increases the 
effectiveness of endometriosis treatment. MethOds: We systematically reviewed 
studies published from 1996 to 2012. We evaluated two interventions (medical & 
surgical) of endometriosis with two outcomes (reduced costs & increased success/
reduced recurrence time). We compared the outcomes of early (minimal & mild) 
and late (moderate & severe) stage interventions of endometriosis by summarizing 
the studies and listing their relative main outcomes. We also assessed the qual-
ity of the studies by checking (yes or no) whether they conducted a sensitivity 
analysis. Results: Seven studies met the inclusion criteria of enrolling patients 
suffering from endometriosis and reporting costs and effects relating to detection 
and treatment of early and late stage of endometriosis. Early stage interventions are 
less costly and more effective but only two studies conducted a sensitivity analy-
sis. cOnclusiOns: The findings indicate that early detection of endometriosis 
improves the outcomes of endometriosis treatment (both medical and surgical) but 
there are limitations to these findings. The methodological structure of the studies 
was not conformed to analytical robustness and therefore affected the quality of 
results and outcomes reported. This validates the World Endometriosis Research 
Foundation’s recommendation for more high-quality studies on the economic evalu-
ation of endometriosis.
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Objectives: HIV and AIDS is a major cause of premature death and impose a large 
disease burden in Kenya. Antiretroviral treatment (ART) is one of the interventions 
being implemented to mitigate these impacts. Economic studies on the cost and 
health effects of ART are very scarce in developing countries, Kenya included. The 
objectives of this research were to estimate health care utilization, the unit costs of 
services and the cost per life year (LYs) gained of HIV treatment interventions from 
a provider’s perspective. MethOds: A retrospective study of adults on ART and 
those not on ART, had CD4 counts 250 and below at enrolment. Data was collected 
from Mbagathi District Hospital (Mbagathi) (n= 350) and Moi Teaching and Referral 
Hospital (Moi) in Kenya (n= 400). A micro-costing method was used to cost all the 
treatment inputs and Markov modelling estimated the cost-effectiveness analysis, 
lifetime costs and health benefits of HIV treatments in the two hospitals. Results: 
The undiscounted lifetime costs for No-ART in Mbagathi and Moi were, KSh169,123 
($2,260) and KSh184,415 ($2,464) respectively, while life years gained for both hospi-
tals was 2.68 years. The undiscounted lifetime costs for the ART group in Mbagathi 
and Moi were KSh932,071 ($1,245) and KSh1,608,496 ($21,490) respectively while life-
time benefits were 15.85 and 25.56 years for Mbagathi and Moi respectively. At 10% 
discounting rate, the lifetime benefits for No ART for both hospitals was 2.1 years 
and costs were KSh153,807 ($2,055) and KSh166,377 ($2,223) for Mbagathi and Moi 
respectively while the lifetime cost for ART was KSh423,959 ($5,664) and KSh563,647 
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Objectives: Multiple Sclerosis (MS) disease treatment requires high adherence 
levels to maximize medicine effectiveness. It has been shown that comprehensive 
care at home programs in MS improve treatment adherence. In Mexico, average 
adherence levels for MS is less than 80%, therefore, the purpose of this study was 
to evaluate a comprehensive care at home program in patients of the Mexican 
Institute of Social Security with Multiple Sclerosis aimed to improve treatment 
adherence and to increase life expectancy. MethOds: The study design was a cost-
effectiveness analysis from the governmental perspective. The costs for patient 
care were obtained from the Diagnosis-related groups that Mexican Institute of 
Social Security publishes and drugs costs were obtained also from the Institute. 
Costs were expressed in 2013 constant USD. A Markov model with sixty monthly 
cycles was developed. Based on the Expanded Disability Status Scale, we divided 
the model into six possible stages (4 EDSS stages, 2 for relapses according to EDSS 
stage) and death. We analyzed six different medicines (intramuscular interferon 
beta 1a, subcutaneous interferon beta 1a, subcutaneous interferon beta 1b, glati-
ramer acetate, Natalizumab and Fingolimod. Parameters were obtained from MS 
literature in Mexico. ICER per year life gained was estimated and discounted at 5% 
annual rate. Results: The comprehensive care at home program increases life 
expectancy in a range of 6 to 12 months depending on the medicine we were analyz-
ing. ICER is cost-effective ($ 556) in a five-year horizon. The program could increase 
adherence in more than 20 percentage points in the best scenario. cOnclusiOns: 
The comprehensive care at home program could improve patient’s health and qual-
ity of life through increasing treatment adherence, therefore it could be considered 
for implementation beyond the Mexican institute of Social Security.
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Objectives: Hospital care at home programs could improve patient’s health and 
also reduce health system costs. In Mexico, there are few programs that offer this 
service. The purpose of this study was to analyze a hospital care at home program 
in patients of the Mexican Institute of Social Security in Mexico City aimed to avoid 
nosocomial infections and hospital readmissions. MethOds: The study design was 
a cost-effectiveness analysis from the governmental perspective. We considered 540 
potential patients. Through a decision tree model two scenarios were compared: 
1. Inpatient Hospital Care vs. 2. Hospital care at home. First scenario costs were: 
hospitalization (per day) and nosocomial infection. Second scenario cost considered 
was hospital at home care (per day). Both scenarios considered hospital readmission 
costs. All the costs were obtained from the Mexican Institute of Social Security and 
were expressed in 2013 constant USD. Effectiveness parameters were obtained from 
similar programs in Mexico and Spain. As effectiveness measures we considered: 
nosocomial infection avoided, hospital readmission avoided and death avoided in 
a one-year horizon. Univariate sensitivity analysis for costs was performed. We 
estimated the hospital supply extension through bed days avoided. Also budget 
impact analysis was conducted. Results: Hospital care at home program reduces 
21% nosocomial infection, 48% hospital readmission and 5% deaths. The program is 
very cost-effective for nosocomial infection avoided (ICER = $2,435), cost-saver for 
hospital readmission (ICER = $ -1,674) and cost-effective for death avoided (ICER = 
$ 15,223). Hospital supply extension is 1,620 beds per year. Budget impact analysis 
showed that nephroprotection could generate savings of 25% depending on the 
Hospital at home care cost per day. cOnclusiOns: Hospital care at home improve 
patient’s Health, reduces health system costs and expands hospital supply, there-
fore, it could be considered for implementation in our country.
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Objectives: Type 2 diabetes is a progressive disease with 50% loss in insulin-
producing capacity at time of diagnosis, with an average 5% annual thereafter. 
Therefore, many patients with type 2 diabetes (T2DM) require insulin treatment. 
Pharmacists are frontline health care professionals who see patients with T2DM 
frequently and as such they could help them achieve their targets by intervening 
in timely manner. The RxING study assessed the effect of a community pharmacist 
intervention in uncontrolled patients with T2DM treateted with oral hypoglycemic 
agents. Those patients were prescribed insulin glargine and followed up for 26 weeks 
by their pharmacist. At endpoint, the average A1c reduction was 1.8% (95%CI 1.4 to 
2). The objective was to assess the cost-effectiveness of having pharmacists’ early 
intervention in prescribing insulin. MethOds: The IMS CORE Diabetes Model, a 
Markov structure and Monte Carlo simulation model was used to assess compli-
cations and disutilities. Health utility and cost data were obtained from recently 
published Canadian publications. The efficacy of insulin in terms of HbA1c reduction, 
and corresponding rates of hypoglycemia were obtained from the RxING study. The 
base case analyses examined the effects of having pharmacist prescribe insulin 
1, 2 and 3 years earlier than a physician. Results: Having pharmacists prescribe 
insulin 1 year earlier than a physician resulted in an incremental cost savings of 
$790 (CDN$) and a gain of 0.048 QALYs per patient. Early pharmacist prescription of 
insulin by 2 years resulted in an increment cost savings of $687 (CDN$) and a gain 
of 0.075 QALYs per year. At 3 years earlier the results were a cost savings of $105 
and a gain of 0.086 QALYs. cOnclusiOns: Having pharmacists initiate insulin 
sooner in uncontrolled T2DM results in cost-savings and delays the development of 
